- Home
- STX vs JNJ Comparison
STX vs JNJ Comparison
Compare STX & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STX | JNJ |
|---|---|---|
| Founded | 1978 | 1886 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2B | 542.4B |
| IPO Year | 2002 | 2003 |
Fundamental Metrics
Financial Performance| Metric | STX | JNJ |
|---|---|---|
| Price | $911.62 | $254.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 20 |
| Target Price | ★ $604.14 | $238.20 |
| AVG Volume (30 Days) | 3.5M | ★ 7.7M |
| Earning Date | 04-28-2026 | 04-14-2026 |
| Dividend Yield | 0.46% | ★ 2.36% |
| EPS Growth | ★ 328.48 | 90.50 |
| EPS | ★ 8.29 | 2.14 |
| Revenue | ★ $7,384,000,000.00 | N/A |
| Revenue This Year | $27.73 | $6.63 |
| Revenue Next Year | $25.06 | $7.43 |
| P/E Ratio | $123.38 | ★ $114.54 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $138.31 | $151.52 |
| 52 Week High | $1,145.00 | $251.71 |
Technical Indicators
Market Signals| Indicator | STX | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 72.20 |
| Support Level | $801.89 | $233.83 |
| Resistance Level | $966.80 | N/A |
| Average True Range (ATR) | 71.82 | 5.13 |
| MACD | -9.29 | 1.78 |
| Stochastic Oscillator | 29.81 | 99.24 |
Price Performance
Historical ComparisonAbout STX Seagate Technology Holdings PLC (Ireland)
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.